An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.
In: Expert Review of Pharmacoeconomics & Outcomes Research, Jg. 18 (2018-08-01), Heft 4, S. 435-446
academicJournal
Zugriff:
Background: the APICE study evaluates the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel - Nab-P) + gemcitabine (G) vs G alone in metastatic pancreatic cancer (MPC) from the Italian National Health Service (INHS) standpoint. Research Design and Methods: A 4-year, 4 health states (progression-free; progressed; end of life; death) Markov model based on the MPACT trial was developed to estimate costs (Euro [€], 2017 values), and quality-adjusted life years (QALYs). Patients were assumed to receive intravenously Nab-P 125 mg/m2 + G 1000 mg/m2 on days 1, 8, and 15 every 4 weeks or G alone 1000 mg/m2 weekly for 7 out of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles) until progression. One-way and probabilistic sensitivity analyses explored the uncertainty surrounding the baseline incremental cost-utility ratio (ICUR). Results: Nab-P + G totals 0.154 incremental QALYs and €7082.68 incremental costs vs G alone. ICUR (€46,021.58) is lower than the informal threshold value of €87,330 adopted by the Italian Medicines Agency during 2010-2013 for reimbursing oncological drugs. Sensitivity analyses confirmed the robustness of the baseline findings. Conclusions: Nab-P + G in MPC patients can be considered cost-effective for the INHS. [ABSTRACT FROM AUTHOR]
Copyright of Expert Review of Pharmacoeconomics & Outcomes Research is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.
|
---|---|
Autor/in / Beteiligte Person: | Lazzaro, Carlo ; Barone, Carlo ; Caprioni, Francesco ; Cascinu, Stefano ; Falcone, Alfredo ; Maiello, Evaristo ; Milella, Michele ; Pinto, Carmine ; Reni, Michele ; Tortora, Giampaolo |
Zeitschrift: | Expert Review of Pharmacoeconomics & Outcomes Research, Jg. 18 (2018-08-01), Heft 4, S. 435-446 |
Veröffentlichung: | 2018 |
Medientyp: | academicJournal |
ISSN: | 1473-7167 (print) |
DOI: | 10.1080/14737167.2018.1464394 |
Schlagwort: |
|
Sonstiges: |
|